Related Experiment Video
Updated: Feb 13, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Does Pediatric Obstructive Sleep Apnea Syndrome Cause Systemic Microvascular Dysfunction?
Hasan Emre Koçak1, Ayşe Şermin Filiz Acipayam2, Harun Acipayam1
1Department of Otorhinolaryngology-Head and Neck Surgery, Bakirköy Dr. Sadi Konuk Training and Research Hospital.
Insights
Pediatric obstructive sleep apnea syndrome (OSAS) from adenoid hypertrophy does not cause early microvascular dysfunction or cardiovascular risk. This study found no significant differences in capillary density or reactive hyperemia in children with OSAS.
Area of Science:
- Pediatric Pulmonology
- Cardiovascular Research
- Sleep Medicine
Background:
- Obstructive sleep apnea syndrome (OSAS) in children, often due to adenoid hypertrophy, is a growing concern.
- The potential impact of pediatric OSAS on systemic microvascular function remains incompletely understood.
- Early identification of cardiovascular risks associated with pediatric OSAS is crucial for timely intervention.
Purpose of the Study:
- To investigate whether pediatric OSAS secondary to adenoid hypertrophy leads to systemic microvascular dysfunction.
- To assess potential early cardiovascular risks in children diagnosed with OSAS.
- To evaluate microvascular parameters in relation to the severity of OSAS.
Main Methods:
- A prospective, single-blinded, case-control study involving 81 pediatric patients with OSAS and 26 healthy controls.
- OSAS severity was categorized as mild, moderate, or severe based on lateral nasopharynx X-ray.
- Videocapillaroscopy assessed nailfold capillary density (CD) and postocclusive reactive hyperemia (PORH) to evaluate microvascular function.
Main Results:
- No statistically significant differences were observed in capillary density (CD) among the control group and the mild, moderate, and severe OSAS groups (P > 0.05).
- Postocclusive reactive hyperemia (PORH) measurements also showed no significant variations across the different OSAS severity groups and the control group (P > 0.05).
- The duration of symptoms in OSAS patients ranged from 6 months to less than 1 year.
Conclusions:
- Pediatric OSAS secondary to adenoid hypertrophy does not appear to cause systemic microvascular dysfunction in the early stages.
- The study suggests that early-stage pediatric OSAS, as evaluated by these microvascular parameters, does not carry an immediate cardiovascular risk.
- Further research may be warranted to explore long-term effects or other potential indicators of cardiovascular risk in this population.
Abstract:
The aim of this study was to evaluate whether pediatric obstructive sleep apnea syndrome (OSAS) secondary to adenoid hypertrophy causes systemic microvascular dysfunction. This is a prospective single-blinded case-control study. As the patient group, 81 patients diagnosed to have OSAS secondary to adenoid hypertrophy at our hospital between January 2016 and May 2016; as the control group, 26 healthy pediatric volunteers who presented to the hospital for health screening were included in this study. Three groups of OSAS patients were defined as mild, moderate, and severe respectively, according to the lateral nasopharynx x-ray. Patients with comorbid diseases were excluded from the study. For microvascular dysfunction, videocapillaroscopic evaluation was performed at the nailfold and capillary density (CD) and postocclusive reactive hyperemia (PORH) values were measured and statistical analysis between the groups was performed. The duration of complaints in all patients with OSAS was at least 6 months and <1 year. CD measurement in the control group and mild, moderate, and severe OSAS group was 94.1 ± 7.9, 96.9 ± 11, 94.7 ± 8.4, and 93.7 ± 9.4, respectively, with no significant difference between the groups (P > 0.05). PORH measurement in the control group and mild, moderate, and severe OSAS group was 95.6 ± 8.6, 97.9 ± 10.1, 96 ± 8.7, and 93.9 ± 9.3, respectively, with no significant difference between the groups (P > 0.05). OSAS secondary to adenoid hypertrophy in pediatric patients was demonstrated to cause no dysfunction in microvascular circulation and carried no cardiovascular risk in the early period.
More Related Videos
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...
Understanding Sleep
The circadian rhythm, a nearly 24-hour cycle, is deeply influenced by environmental light cues. Light exposure directly affects the hypothalamus, which in turn regulates...
Sleepwalking and Sleep Talking
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...